<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835770</url>
  </required_header>
  <id_info>
    <org_study_id>109MS303</org_study_id>
    <secondary_id>2008-004753-14</secondary_id>
    <nct_id>NCT00835770</nct_id>
  </id_info>
  <brief_title>BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)</brief_title>
  <acronym>ENDORSE</acronym>
  <official_title>A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the long-term safety profile of BG00012&#xD;
      (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term&#xD;
      efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further&#xD;
      the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic&#xD;
      resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301&#xD;
      (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on&#xD;
      health economics assessments and the visual function test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The initial BG00012 dosage for the extension study (240 mg BID or 240 mg TID) was the same as&#xD;
      that used in the Phase 3 Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451).&#xD;
      Subsequent to the initiation of this study, BG00012 was approved in several countries for the&#xD;
      treatment of MS at a dose of 240 mg BID. For this reason, all participants continuing in this&#xD;
      study will receive the currently marketed dose of 240 mg BID.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2009</start_date>
  <completion_date type="Actual">November 8, 2019</completion_date>
  <primary_completion_date type="Actual">November 8, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>Day 1 up to Week 561</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had Relapses</measure>
    <time_frame>Day 1 up to Week 384</time_frame>
    <description>Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate (ARR)</measure>
    <time_frame>Day 1 up to Week 384</time_frame>
    <description>The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of participant-years followed in the period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384</measure>
    <time_frame>Baseline, Week 384</time_frame>
    <description>EDSS scale ranges from 0 (Normal neurological exam, no disability) to 10 (Death) in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. Sustained disability progression was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS ≥1.0 that was sustained for at least 24 weeks, or a 1.5 point increase on the EDSS from a baseline EDSS =0 that was sustained for at least 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline up to Week 288</time_frame>
    <description>The Gd-enhancing lesions was evaluated using MRI technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline up to Week 288</time_frame>
    <description>The Gd-enhancing lesions was evaluated using MRI technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline up to Week 288</time_frame>
    <description>The T2 lesions was evaluated using MRI technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline up to Week 288</time_frame>
    <description>The T2 lesions was evaluated using MRI technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline up to Week 288</time_frame>
    <description>The T1 hypointense lesions was evaluated using MRI technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline up to Week 288</time_frame>
    <description>The T1 hypointense lesions was evaluated using MRI technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Brain Atrophy</measure>
    <time_frame>Baseline up to Week 288</time_frame>
    <description>Brain atrophy was measured using magnetic resonance imaging (MRI) technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Magnetization Transfer Ratio (MTR)</measure>
    <time_frame>Baseline up to Week 288</time_frame>
    <description>Magnetization Transfer Ratio (MTR) was measured using MRI technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384</measure>
    <time_frame>Baseline, Week 384</time_frame>
    <description>The SF-36 is a brief (36-item) scale reflecting the impact of both dysfunctions and general health perception the questionnaire measures: 1.physical function (PF),2. role physical (RF),3. bodily pain (BP),4. role emotional (RE),5. social function (SF), 6. general health (GH),7. vitality (VT), 8. mental health (MH). Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score), with higher scores indicating better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384</measure>
    <time_frame>Baseline, Week 384</time_frame>
    <description>The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. The EQ-5D provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to indicate whether he or she has (1) &quot;no problems&quot;, (2) &quot;some problems&quot;, or (3) &quot;severe problems&quot;. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384</measure>
    <time_frame>Baseline, Week 384</time_frame>
    <description>The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. In EQ-VAS participants are asked to rate their current health on a 20 centimeter (cm) scale from 0 to 100 where 0 represents &quot;worst imaginable health state&quot; and 100 represents &quot;best imaginable health state&quot;. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Function Test Scores at Week 384</measure>
    <time_frame>Baseline, Week 384</time_frame>
    <description>Participants were tested using the contrast level of 100%, 2.5%, and 1.25% charts, and the scores were defined as the number of letters identified correctly for each chart (the maximum score was 60). Higher scores indicate better functioning. A positive change from baseline indicates better functioning.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1736</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>BG00012 plus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BG00012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dimethyl fumarate</intervention_name>
    <description>BG00012 capsules</description>
    <arm_group_label>BG00012</arm_group_label>
    <arm_group_label>BG00012 plus placebo</arm_group_label>
    <other_name>BG00012</other_name>
    <other_name>Tecfidera</other_name>
    <other_name>DMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules taken to maintain the blind in the 240 mg BID treatment group.</description>
    <arm_group_label>BG00012 plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        -Subjects who participated in and completed as per protocol previous BG00012 clinical&#xD;
        studies 109MS301 (NCT00420212) or 109MS302 (NCT00451451).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any significant change in medical history from 109MS301 or 109MS302 that would have&#xD;
             excluded subject's participation from their previous study.&#xD;
&#xD;
          -  Subjects from 109MS301 or 109MS302 who discontinued oral study treatment due to an AE&#xD;
             or due to reasons other than protocol-defined relapse/disability progression.&#xD;
&#xD;
          -  Subjects from 109MS301 or 109MS302 who discontinued study treatment due to disability&#xD;
             progression or relapses and did not follow the modified visit schedule up to Week 96.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>research Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <zip>11772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Ohio</state>
        <zip>44811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rumford</city>
        <state>Rhode Island</state>
        <zip>02916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Issaquah</city>
        <state>Washington</state>
        <zip>98029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chatswood</city>
        <zip>2067</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geelong</city>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sydney</city>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belarus</city>
        <state>Gomel</state>
        <zip>246029</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belarus</city>
        <state>Vitebsk</state>
        <zip>210023</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minsk</city>
        <zip>220114</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Damme</city>
        <zip>8340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Diepenbeek</city>
        <zip>3590</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hechtel-Eksel</city>
        <zip>3940</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodelinsart</city>
        <zip>6042</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sint-Truiden</city>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuzla</city>
        <zip>75000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lévis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nova Scotia</city>
        <zip>B3H 4K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regina</city>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moravska Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opava</city>
        <zip>746 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava - Vítkovice</city>
        <zip>70300</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berg</city>
        <state>Bavaria</state>
        <zip>82335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Steinfurt</city>
        <state>Ibbenbueren</state>
        <zip>49477</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10961</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <zip>45257</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22083</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30171</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koeln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munich (München)</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <zip>700068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ludhiana</city>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ludhiana</city>
        <zip>141008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mangalore</city>
        <zip>575002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <zip>400054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1015</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>44610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <zip>03310</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <zip>58000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chisinau</city>
        <zip>2001</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chisinau</city>
        <zip>2028</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-299</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-594</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lódz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plewiska</city>
        <zip>62-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-539</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-215</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guaynabo</city>
        <zip>00968</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>011464</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>022104</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400012</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Târgu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Martin</city>
        <zip>03659</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Córdoba</city>
        <zip>14011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odessa</city>
        <zip>65117</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E1 2EF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E1 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stoke on Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>North Macedonia</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Guatemala</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
  </removed_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <results_first_submitted>October 20, 2020</results_first_submitted>
  <results_first_submitted_qc>December 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2020</results_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>remitting</keyword>
  <keyword>oral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT00835770/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT00835770/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 298 investigative sites from 03 February 2009 to 08 November 2019.</recruitment_details>
      <pre_assignment_details>The study included participants who completed studies NCT00420212 and NCT00451451. A total of 1736 participants were treated in the open label phase extension study NCT00835770, out of which 759 completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BG00012 240 mg BID</title>
          <description>Participants received BG00012 240 milligram (mg), 2 capsules (120 mg each) orally, twice a day (BID) and 2 matching placebo capsules once a day (QD) for up to 8 years.</description>
        </group>
        <group group_id="P2">
          <title>BG00012 240 mg TID</title>
          <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, three times a day (TID) for up to 8 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="868"/>
                <participants group_id="P2" count="868"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="384"/>
                <participants group_id="P2" count="375"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="484"/>
                <participants group_id="P2" count="493"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>MS Relapse</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>MS Progression</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="124"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) population included participants who had entered study NCT00835770 and received at least one dose of study treatment. Data for ethnicity was not evaluated in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>BG00012 240 mg BID</title>
          <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years.</description>
        </group>
        <group group_id="B2">
          <title>BG00012 240 mg TID</title>
          <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="868"/>
            <count group_id="B2" value="868"/>
            <count group_id="B3" value="1736"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="8.93"/>
                    <measurement group_id="B2" value="40.1" spread="9.23"/>
                    <measurement group_id="B3" value="39.8" spread="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="616"/>
                    <measurement group_id="B2" value="596"/>
                    <measurement group_id="B3" value="1212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="594"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported Due To Confidentiality Regulations</title>
                  <measurement_list>
                    <measurement group_id="B1" value="459"/>
                    <measurement group_id="B2" value="439"/>
                    <measurement group_id="B3" value="898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
        <time_frame>Day 1 up to Week 561</time_frame>
        <population>Safety population included all participants who had any post-baseline safety follow-up in study NCT00835770, defined as any treatment emergent AE in study NCT00835770 or any post-baseline laboratory, vital signs, or physical exam assessment in study NCT00835770, and received at least one dose of study treatment in study NCT00835770.</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs)</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
          <population>Safety population included all participants who had any post-baseline safety follow-up in study NCT00835770, defined as any treatment emergent AE in study NCT00835770 or any post-baseline laboratory, vital signs, or physical exam assessment in study NCT00835770, and received at least one dose of study treatment in study NCT00835770.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="868"/>
                <count group_id="O2" value="868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="824"/>
                    <measurement group_id="O2" value="814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had Relapses</title>
        <description>Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours.</description>
        <time_frame>Day 1 up to Week 384</time_frame>
        <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. Data for this outcome measure (OM) was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had Relapses</title>
          <description>Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours.</description>
          <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. Data for this outcome measure (OM) was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="502"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="248"/>
                <count group_id="O5" value="118"/>
                <count group_id="O6" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Relapse Rate (ARR)</title>
        <description>The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of participant-years followed in the period.</description>
        <time_frame>Day 1 up to Week 384</time_frame>
        <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate (ARR)</title>
          <description>The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of participant-years followed in the period.</description>
          <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>relapses per participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="502"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="248"/>
                <count group_id="O5" value="118"/>
                <count group_id="O6" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.159"/>
                    <measurement group_id="O2" value="0.179"/>
                    <measurement group_id="O3" value="0.200"/>
                    <measurement group_id="O4" value="0.199"/>
                    <measurement group_id="O5" value="0.184"/>
                    <measurement group_id="O6" value="0.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384</title>
        <description>EDSS scale ranges from 0 (Normal neurological exam, no disability) to 10 (Death) in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. Sustained disability progression was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS ≥1.0 that was sustained for at least 24 weeks, or a 1.5 point increase on the EDSS from a baseline EDSS =0 that was sustained for at least 24 weeks.</description>
        <time_frame>Baseline, Week 384</time_frame>
        <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384</title>
          <description>EDSS scale ranges from 0 (Normal neurological exam, no disability) to 10 (Death) in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. Sustained disability progression was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS ≥1.0 that was sustained for at least 24 weeks, or a 1.5 point increase on the EDSS from a baseline EDSS =0 that was sustained for at least 24 weeks.</description>
          <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="502"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="248"/>
                <count group_id="O5" value="118"/>
                <count group_id="O6" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                    <count group_id="O2" value="502"/>
                    <count group_id="O3" value="249"/>
                    <count group_id="O4" value="248"/>
                    <count group_id="O5" value="118"/>
                    <count group_id="O6" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="1.251"/>
                    <measurement group_id="O2" value="2.43" spread="1.144"/>
                    <measurement group_id="O3" value="2.50" spread="1.135"/>
                    <measurement group_id="O4" value="2.54" spread="1.218"/>
                    <measurement group_id="O5" value="2.57" spread="1.249"/>
                    <measurement group_id="O6" value="2.68" spread="1.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="1.160"/>
                    <measurement group_id="O2" value="0.26" spread="1.213"/>
                    <measurement group_id="O3" value="0.37" spread="1.328"/>
                    <measurement group_id="O4" value="0.53" spread="1.278"/>
                    <measurement group_id="O5" value="0.39" spread="1.217"/>
                    <measurement group_id="O6" value="0.49" spread="1.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
        <description>The Gd-enhancing lesions was evaluated using MRI technique.</description>
        <time_frame>Baseline up to Week 288</time_frame>
        <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
          <description>The Gd-enhancing lesions was evaluated using MRI technique.</description>
          <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="195"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.87"/>
                    <measurement group_id="O2" value="0.4" spread="1.29"/>
                    <measurement group_id="O3" value="0.2" spread="0.66"/>
                    <measurement group_id="O4" value="0.3" spread="1.14"/>
                    <measurement group_id="O5" value="0.5" spread="1.19"/>
                    <measurement group_id="O6" value="0.4" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="186"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="75"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.77"/>
                    <measurement group_id="O2" value="0.4" spread="1.28"/>
                    <measurement group_id="O3" value="0.1" spread="0.38"/>
                    <measurement group_id="O4" value="0.2" spread="0.82"/>
                    <measurement group_id="O5" value="0.6" spread="1.33"/>
                    <measurement group_id="O6" value="0.3" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                    <count group_id="O2" value="159"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="60"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.66"/>
                    <measurement group_id="O2" value="0.4" spread="1.30"/>
                    <measurement group_id="O3" value="0.2" spread="0.44"/>
                    <measurement group_id="O4" value="0.1" spread="0.29"/>
                    <measurement group_id="O5" value="0.5" spread="2.48"/>
                    <measurement group_id="O6" value="0.3" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="149"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.02"/>
                    <measurement group_id="O2" value="0.5" spread="1.85"/>
                    <measurement group_id="O3" value="0.5" spread="1.72"/>
                    <measurement group_id="O4" value="0.3" spread="0.96"/>
                    <measurement group_id="O5" value="0.2" spread="0.60"/>
                    <measurement group_id="O6" value="0.6" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.14"/>
                    <measurement group_id="O2" value="0.5" spread="2.29"/>
                    <measurement group_id="O3" value="0.2" spread="0.50"/>
                    <measurement group_id="O4" value="0.2" spread="0.51"/>
                    <measurement group_id="O5" value="0.2" spread="0.58"/>
                    <measurement group_id="O6" value="0.3" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.74"/>
                    <measurement group_id="O2" value="0.5" spread="1.81"/>
                    <measurement group_id="O3" value="0.1" spread="0.40"/>
                    <measurement group_id="O4" value="0.7" spread="2.76"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.3" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
        <description>The Gd-enhancing lesions was evaluated using MRI technique.</description>
        <time_frame>Baseline up to Week 288</time_frame>
        <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
          <description>The Gd-enhancing lesions was evaluated using MRI technique.</description>
          <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>millimeter cube (mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="220"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" spread="179.28"/>
                    <measurement group_id="O2" value="48.6" spread="205.43"/>
                    <measurement group_id="O3" value="96.0" spread="260.79"/>
                    <measurement group_id="O4" value="142.5" spread="459.76"/>
                    <measurement group_id="O5" value="37.1" spread="138.82"/>
                    <measurement group_id="O6" value="41.7" spread="116.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="526.51"/>
                    <measurement group_id="O2" value="70.0" spread="366.63"/>
                    <measurement group_id="O3" value="18.8" spread="91.47"/>
                    <measurement group_id="O4" value="25.3" spread="108.19"/>
                    <measurement group_id="O5" value="42.5" spread="123.67"/>
                    <measurement group_id="O6" value="42.7" spread="148.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="185"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" spread="245.14"/>
                    <measurement group_id="O2" value="56.1" spread="271.29"/>
                    <measurement group_id="O3" value="27.7" spread="204.80"/>
                    <measurement group_id="O4" value="13.3" spread="67.01"/>
                    <measurement group_id="O5" value="64.3" spread="183.16"/>
                    <measurement group_id="O6" value="22.3" spread="60.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="155"/>
                    <count group_id="O2" value="160"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="59"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="291.14"/>
                    <measurement group_id="O2" value="47.0" spread="169.68"/>
                    <measurement group_id="O3" value="18.8" spread="66.15"/>
                    <measurement group_id="O4" value="3.8" spread="25.03"/>
                    <measurement group_id="O5" value="42.6" spread="142.55"/>
                    <measurement group_id="O6" value="92.9" spread="397.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" spread="217.89"/>
                    <measurement group_id="O2" value="54.5" spread="251.31"/>
                    <measurement group_id="O3" value="45.8" spread="156.88"/>
                    <measurement group_id="O4" value="19.9" spread="79.19"/>
                    <measurement group_id="O5" value="12.0" spread="40.56"/>
                    <measurement group_id="O6" value="55.1" spread="169.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="52"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" spread="650.06"/>
                    <measurement group_id="O2" value="69.3" spread="374.67"/>
                    <measurement group_id="O3" value="21.7" spread="77.87"/>
                    <measurement group_id="O4" value="14.1" spread="45.22"/>
                    <measurement group_id="O5" value="17.5" spread="46.19"/>
                    <measurement group_id="O6" value="17.1" spread="48.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="93.28"/>
                    <measurement group_id="O2" value="53.1" spread="250.87"/>
                    <measurement group_id="O3" value="7.9" spread="30.09"/>
                    <measurement group_id="O4" value="230.2" spread="1092.11"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="34.1" spread="102.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
        <description>The T2 lesions was evaluated using MRI technique.</description>
        <time_frame>Baseline up to Week 288</time_frame>
        <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
          <description>The T2 lesions was evaluated using MRI technique.</description>
          <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="201"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="81"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="4.07"/>
                    <measurement group_id="O2" value="2.2" spread="6.15"/>
                    <measurement group_id="O3" value="2.7" spread="4.96"/>
                    <measurement group_id="O4" value="2.4" spread="5.45"/>
                    <measurement group_id="O5" value="3.4" spread="6.57"/>
                    <measurement group_id="O6" value="2.1" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="191"/>
                    <count group_id="O2" value="192"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="8.35"/>
                    <measurement group_id="O2" value="4.1" spread="10.01"/>
                    <measurement group_id="O3" value="3.8" spread="7.24"/>
                    <measurement group_id="O4" value="2.9" spread="6.78"/>
                    <measurement group_id="O5" value="4.9" spread="8.51"/>
                    <measurement group_id="O6" value="3.4" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="163"/>
                    <count group_id="O2" value="168"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="63"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="9.81"/>
                    <measurement group_id="O2" value="5.2" spread="10.01"/>
                    <measurement group_id="O3" value="4.0" spread="7.27"/>
                    <measurement group_id="O4" value="4.3" spread="10.12"/>
                    <measurement group_id="O5" value="5.7" spread="9.45"/>
                    <measurement group_id="O6" value="5.2" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="61"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="14.04"/>
                    <measurement group_id="O2" value="7.5" spread="15.14"/>
                    <measurement group_id="O3" value="5.6" spread="10.09"/>
                    <measurement group_id="O4" value="5.6" spread="14.19"/>
                    <measurement group_id="O5" value="5.5" spread="9.94"/>
                    <measurement group_id="O6" value="5.6" spread="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="17.09"/>
                    <measurement group_id="O2" value="9.5" spread="20.33"/>
                    <measurement group_id="O3" value="8.2" spread="14.87"/>
                    <measurement group_id="O4" value="7.7" spread="17.89"/>
                    <measurement group_id="O5" value="6.8" spread="11.74"/>
                    <measurement group_id="O6" value="7.5" spread="16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="18.53"/>
                    <measurement group_id="O2" value="12.4" spread="28.23"/>
                    <measurement group_id="O3" value="7.5" spread="13.89"/>
                    <measurement group_id="O4" value="10.4" spread="22.05"/>
                    <measurement group_id="O5" value="8.9" spread="15.04"/>
                    <measurement group_id="O6" value="6.0" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
        <description>The T2 lesions was evaluated using MRI technique.</description>
        <time_frame>Baseline up to Week 288</time_frame>
        <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
          <description>The T2 lesions was evaluated using MRI technique.</description>
          <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="220"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10231.9" spread="11214.17"/>
                    <measurement group_id="O2" value="10408.3" spread="12166.80"/>
                    <measurement group_id="O3" value="8883.7" spread="8570.10"/>
                    <measurement group_id="O4" value="10806.3" spread="12060.05"/>
                    <measurement group_id="O5" value="12628.9" spread="11258.69"/>
                    <measurement group_id="O6" value="13044.4" spread="14608.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                    <count group_id="O2" value="199"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9951.9" spread="10750.15"/>
                    <measurement group_id="O2" value="9849.6" spread="10986.36"/>
                    <measurement group_id="O3" value="8992.1" spread="7952.13"/>
                    <measurement group_id="O4" value="10114.5" spread="10121.61"/>
                    <measurement group_id="O5" value="11160.7" spread="9565.55"/>
                    <measurement group_id="O6" value="12979.0" spread="14415.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="190"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10331.3" spread="11359.81"/>
                    <measurement group_id="O2" value="10434.0" spread="12201.38"/>
                    <measurement group_id="O3" value="8645.2" spread="7787.60"/>
                    <measurement group_id="O4" value="9985.7" spread="10715.73"/>
                    <measurement group_id="O5" value="11318.1" spread="9873.73"/>
                    <measurement group_id="O6" value="13974.1" spread="15432.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="167"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="61"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9930.1" spread="10686.26"/>
                    <measurement group_id="O2" value="10280.7" spread="11324.58"/>
                    <measurement group_id="O3" value="8829.4" spread="7482.93"/>
                    <measurement group_id="O4" value="9792.3" spread="9842.28"/>
                    <measurement group_id="O5" value="10188.5" spread="8064.09"/>
                    <measurement group_id="O6" value="12949.7" spread="14036.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="149"/>
                    <count group_id="O2" value="154"/>
                    <count group_id="O3" value="61"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9837.7" spread="10845.04"/>
                    <measurement group_id="O2" value="10760.0" spread="11987.16"/>
                    <measurement group_id="O3" value="9077.6" spread="7794.52"/>
                    <measurement group_id="O4" value="10576.3" spread="12029.26"/>
                    <measurement group_id="O5" value="10421.9" spread="8773.41"/>
                    <measurement group_id="O6" value="11671.5" spread="13124.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10611.2" spread="11633.95"/>
                    <measurement group_id="O2" value="11087.5" spread="12464.90"/>
                    <measurement group_id="O3" value="9711.1" spread="8709.46"/>
                    <measurement group_id="O4" value="10591.4" spread="11613.26"/>
                    <measurement group_id="O5" value="11009.9" spread="9551.94"/>
                    <measurement group_id="O6" value="12254.4" spread="13732.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="121"/>
                    <count group_id="O2" value="122"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9611.8" spread="9447.18"/>
                    <measurement group_id="O2" value="9800.8" spread="11279.84"/>
                    <measurement group_id="O3" value="8819.8" spread="8866.90"/>
                    <measurement group_id="O4" value="10537.6" spread="10684.47"/>
                    <measurement group_id="O5" value="11586.3" spread="9728.19"/>
                    <measurement group_id="O6" value="10404.8" spread="12245.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
        <description>The T1 hypointense lesions was evaluated using MRI technique.</description>
        <time_frame>Baseline up to Week 288</time_frame>
        <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
          <description>The T1 hypointense lesions was evaluated using MRI technique.</description>
          <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="184"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="76"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.13"/>
                    <measurement group_id="O2" value="1.0" spread="2.37"/>
                    <measurement group_id="O3" value="1.8" spread="3.81"/>
                    <measurement group_id="O4" value="1.7" spread="3.71"/>
                    <measurement group_id="O5" value="2.0" spread="4.22"/>
                    <measurement group_id="O6" value="1.3" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="3.63"/>
                    <measurement group_id="O2" value="1.9" spread="3.91"/>
                    <measurement group_id="O3" value="1.8" spread="3.33"/>
                    <measurement group_id="O4" value="2.1" spread="5.00"/>
                    <measurement group_id="O5" value="3.0" spread="5.85"/>
                    <measurement group_id="O6" value="1.9" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="155"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="4.61"/>
                    <measurement group_id="O2" value="2.8" spread="5.19"/>
                    <measurement group_id="O3" value="2.0" spread="3.69"/>
                    <measurement group_id="O4" value="2.6" spread="7.02"/>
                    <measurement group_id="O5" value="3.1" spread="6.20"/>
                    <measurement group_id="O6" value="2.9" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="58"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="7.03"/>
                    <measurement group_id="O2" value="3.4" spread="6.79"/>
                    <measurement group_id="O3" value="2.9" spread="5.12"/>
                    <measurement group_id="O4" value="3.8" spread="10.71"/>
                    <measurement group_id="O5" value="3.3" spread="6.74"/>
                    <measurement group_id="O6" value="3.0" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="136"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="8.25"/>
                    <measurement group_id="O2" value="4.8" spread="9.39"/>
                    <measurement group_id="O3" value="4.0" spread="7.52"/>
                    <measurement group_id="O4" value="4.9" spread="13.30"/>
                    <measurement group_id="O5" value="4.0" spread="8.06"/>
                    <measurement group_id="O6" value="4.2" spread="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="5.72"/>
                    <measurement group_id="O2" value="5.9" spread="12.02"/>
                    <measurement group_id="O3" value="4.5" spread="7.38"/>
                    <measurement group_id="O4" value="3.6" spread="4.51"/>
                    <measurement group_id="O5" value="1.0" spread="1.10"/>
                    <measurement group_id="O6" value="5.6" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
        <description>The T1 hypointense lesions was evaluated using MRI technique.</description>
        <time_frame>Baseline up to Week 288</time_frame>
        <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)</title>
          <description>The T1 hypointense lesions was evaluated using MRI technique.</description>
          <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="220"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3640.1" spread="5598.31"/>
                    <measurement group_id="O2" value="3447.3" spread="4900.96"/>
                    <measurement group_id="O3" value="2754.2" spread="3552.30"/>
                    <measurement group_id="O4" value="3623.1" spread="5549.13"/>
                    <measurement group_id="O5" value="3204.3" spread="4221.55"/>
                    <measurement group_id="O6" value="3572.6" spread="4915.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3829.5" spread="5824.26"/>
                    <measurement group_id="O2" value="3715.5" spread="5112.21"/>
                    <measurement group_id="O3" value="2891.9" spread="3034.00"/>
                    <measurement group_id="O4" value="3936.0" spread="5271.89"/>
                    <measurement group_id="O5" value="3271.0" spread="4157.24"/>
                    <measurement group_id="O6" value="3743.3" spread="5374.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="186"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3841.2" spread="5682.74"/>
                    <measurement group_id="O2" value="3853.7" spread="5428.66"/>
                    <measurement group_id="O3" value="2921.0" spread="3327.93"/>
                    <measurement group_id="O4" value="3849.4" spread="5167.13"/>
                    <measurement group_id="O5" value="3510.4" spread="4672.80"/>
                    <measurement group_id="O6" value="3949.7" spread="5018.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="157"/>
                    <count group_id="O2" value="164"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="58"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3767.4" spread="4969.23"/>
                    <measurement group_id="O2" value="4074.0" spread="5413.85"/>
                    <measurement group_id="O3" value="3145.6" spread="3366.27"/>
                    <measurement group_id="O4" value="4006.9" spread="5062.08"/>
                    <measurement group_id="O5" value="3499.2" spread="4198.50"/>
                    <measurement group_id="O6" value="4126.1" spread="5695.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="145"/>
                    <count group_id="O2" value="149"/>
                    <count group_id="O3" value="60"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3834.9" spread="4942.19"/>
                    <measurement group_id="O2" value="4177.4" spread="5301.68"/>
                    <measurement group_id="O3" value="3385.4" spread="3575.44"/>
                    <measurement group_id="O4" value="4330.0" spread="5136.67"/>
                    <measurement group_id="O5" value="3592.0" spread="4069.39"/>
                    <measurement group_id="O6" value="4089.3" spread="4996.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="55"/>
                    <count group_id="O4" value="52"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4038.6" spread="5145.85"/>
                    <measurement group_id="O2" value="4238.2" spread="5248.84"/>
                    <measurement group_id="O3" value="3406.4" spread="3936.73"/>
                    <measurement group_id="O4" value="3823.9" spread="4274.82"/>
                    <measurement group_id="O5" value="3503.4" spread="3933.75"/>
                    <measurement group_id="O6" value="4057.7" spread="5223.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 288</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3603.3" spread="4394.60"/>
                    <measurement group_id="O2" value="3973.1" spread="5202.05"/>
                    <measurement group_id="O3" value="3350.6" spread="4140.34"/>
                    <measurement group_id="O4" value="4187.5" spread="4835.43"/>
                    <measurement group_id="O5" value="3264.9" spread="3639.91"/>
                    <measurement group_id="O6" value="2959.1" spread="3918.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Brain Atrophy</title>
        <description>Brain atrophy was measured using magnetic resonance imaging (MRI) technique.</description>
        <time_frame>Baseline up to Week 288</time_frame>
        <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Brain Atrophy</title>
          <description>Brain atrophy was measured using magnetic resonance imaging (MRI) technique.</description>
          <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="162"/>
                    <count group_id="O3" value="56"/>
                    <count group_id="O4" value="64"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.206" spread="1.1006"/>
                    <measurement group_id="O2" value="-1.263" spread="1.0848"/>
                    <measurement group_id="O3" value="-1.487" spread="1.3086"/>
                    <measurement group_id="O4" value="-1.320" spread="1.4021"/>
                    <measurement group_id="O5" value="-1.496" spread="1.1316"/>
                    <measurement group_id="O6" value="-1.414" spread="1.1882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="144"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.372" spread="1.1382"/>
                    <measurement group_id="O2" value="-1.500" spread="1.0893"/>
                    <measurement group_id="O3" value="-1.589" spread="1.3630"/>
                    <measurement group_id="O4" value="-1.775" spread="1.7191"/>
                    <measurement group_id="O5" value="-1.883" spread="1.2383"/>
                    <measurement group_id="O6" value="-1.810" spread="1.4556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="44"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.708" spread="1.4109"/>
                    <measurement group_id="O2" value="-1.876" spread="1.2604"/>
                    <measurement group_id="O3" value="-2.139" spread="1.5884"/>
                    <measurement group_id="O4" value="-2.353" spread="1.7897"/>
                    <measurement group_id="O5" value="-2.386" spread="1.3168"/>
                    <measurement group_id="O6" value="-2.252" spread="2.2124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.138" spread="1.6831"/>
                    <measurement group_id="O2" value="-2.117" spread="1.4000"/>
                    <measurement group_id="O3" value="-2.230" spread="1.7755"/>
                    <measurement group_id="O4" value="-2.476" spread="1.7062"/>
                    <measurement group_id="O5" value="-2.645" spread="1.2284"/>
                    <measurement group_id="O6" value="-2.417" spread="2.0486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.313" spread="1.6309"/>
                    <measurement group_id="O2" value="-2.253" spread="1.3721"/>
                    <measurement group_id="O3" value="-2.271" spread="1.4817"/>
                    <measurement group_id="O4" value="-2.593" spread="1.9043"/>
                    <measurement group_id="O5" value="-2.249" spread="1.2985"/>
                    <measurement group_id="O6" value="-2.790" spread="2.2188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 288</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.216" spread="1.5744"/>
                    <measurement group_id="O2" value="-2.271" spread="1.2193"/>
                    <measurement group_id="O3" value="-2.470" spread="1.6757"/>
                    <measurement group_id="O4" value="-2.849" spread="1.9648"/>
                    <measurement group_id="O5" value="-2.657" spread="1.7051"/>
                    <measurement group_id="O6" value="-2.496" spread="1.3699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Magnetization Transfer Ratio (MTR)</title>
        <description>Magnetization Transfer Ratio (MTR) was measured using MRI technique.</description>
        <time_frame>Baseline up to Week 288</time_frame>
        <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Magnetization Transfer Ratio (MTR)</title>
          <description>Magnetization Transfer Ratio (MTR) was measured using MRI technique.</description>
          <population>MRI population. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="118"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.325" spread="5.4932"/>
                    <measurement group_id="O2" value="-0.383" spread="4.8621"/>
                    <measurement group_id="O3" value="1.034" spread="7.3548"/>
                    <measurement group_id="O4" value="-0.567" spread="4.4766"/>
                    <measurement group_id="O5" value="-0.081" spread="13.6416"/>
                    <measurement group_id="O6" value="-0.334" spread="1.5103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.427" spread="6.6493"/>
                    <measurement group_id="O2" value="-0.532" spread="4.9880"/>
                    <measurement group_id="O3" value="1.630" spread="7.6584"/>
                    <measurement group_id="O4" value="-0.947" spread="7.0771"/>
                    <measurement group_id="O5" value="-4.269" spread="12.6065"/>
                    <measurement group_id="O6" value="0.215" spread="1.4270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="45"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.042" spread="9.2548"/>
                    <measurement group_id="O2" value="0.509" spread="7.2692"/>
                    <measurement group_id="O3" value="1.525" spread="8.6421"/>
                    <measurement group_id="O4" value="1.411" spread="12.2825"/>
                    <measurement group_id="O5" value="-4.460" spread="10.3887"/>
                    <measurement group_id="O6" value="3.119" spread="8.1676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 192</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="42"/>
                    <count group_id="O4" value="41"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.038" spread="10.8680"/>
                    <measurement group_id="O2" value="0.955" spread="8.6105"/>
                    <measurement group_id="O3" value="3.012" spread="9.3831"/>
                    <measurement group_id="O4" value="3.103" spread="13.0046"/>
                    <measurement group_id="O5" value="1.384" spread="15.7611"/>
                    <measurement group_id="O6" value="3.841" spread="10.8600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="42"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="15.6190"/>
                    <measurement group_id="O2" value="1.647" spread="8.3094"/>
                    <measurement group_id="O3" value="3.213" spread="9.6621"/>
                    <measurement group_id="O4" value="4.108" spread="13.8103"/>
                    <measurement group_id="O5" value="2.959" spread="16.8386"/>
                    <measurement group_id="O6" value="0.673" spread="25.9962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 288</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="4.0206"/>
                    <measurement group_id="O2" value="-0.391" spread="4.6415"/>
                    <measurement group_id="O3" value="-0.666" spread="2.0741"/>
                    <measurement group_id="O4" value="-0.622" spread="2.2922"/>
                    <measurement group_id="O5" value="-0.466" spread="0.9410"/>
                    <measurement group_id="O6" value="-1.114" spread="2.4539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384</title>
        <description>The SF-36 is a brief (36-item) scale reflecting the impact of both dysfunctions and general health perception the questionnaire measures: 1.physical function (PF),2. role physical (RF),3. bodily pain (BP),4. role emotional (RE),5. social function (SF), 6. general health (GH),7. vitality (VT), 8. mental health (MH). Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score), with higher scores indicating better function.</description>
        <time_frame>Baseline, Week 384</time_frame>
        <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384</title>
          <description>The SF-36 is a brief (36-item) scale reflecting the impact of both dysfunctions and general health perception the questionnaire measures: 1.physical function (PF),2. role physical (RF),3. bodily pain (BP),4. role emotional (RE),5. social function (SF), 6. general health (GH),7. vitality (VT), 8. mental health (MH). Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score), with higher scores indicating better function.</description>
          <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="502"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="248"/>
                <count group_id="O5" value="118"/>
                <count group_id="O6" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Physical Functioning Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="494"/>
                    <count group_id="O2" value="487"/>
                    <count group_id="O3" value="244"/>
                    <count group_id="O4" value="240"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.48" spread="25.938"/>
                    <measurement group_id="O2" value="71.78" spread="24.849"/>
                    <measurement group_id="O3" value="69.67" spread="24.481"/>
                    <measurement group_id="O4" value="67.97" spread="26.279"/>
                    <measurement group_id="O5" value="69.10" spread="25.226"/>
                    <measurement group_id="O6" value="68.20" spread="25.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: Physical Functioning Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="21.972"/>
                    <measurement group_id="O2" value="-4.79" spread="24.641"/>
                    <measurement group_id="O3" value="-7.37" spread="22.253"/>
                    <measurement group_id="O4" value="-6.89" spread="23.194"/>
                    <measurement group_id="O5" value="-6.19" spread="21.719"/>
                    <measurement group_id="O6" value="-6.25" spread="28.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Role-Physical Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="494"/>
                    <count group_id="O2" value="486"/>
                    <count group_id="O3" value="244"/>
                    <count group_id="O4" value="238"/>
                    <count group_id="O5" value="114"/>
                    <count group_id="O6" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.46" spread="41.254"/>
                    <measurement group_id="O2" value="58.42" spread="41.280"/>
                    <measurement group_id="O3" value="56.35" spread="40.896"/>
                    <measurement group_id="O4" value="59.87" spread="41.747"/>
                    <measurement group_id="O5" value="55.26" spread="40.390"/>
                    <measurement group_id="O6" value="53.57" spread="42.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: Role-Physical Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="232"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="48.259"/>
                    <measurement group_id="O2" value="-2.75" spread="47.283"/>
                    <measurement group_id="O3" value="-10.00" spread="43.188"/>
                    <measurement group_id="O4" value="-8.24" spread="53.177"/>
                    <measurement group_id="O5" value="-12.21" spread="40.595"/>
                    <measurement group_id="O6" value="-1.04" spread="54.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Bodily-Pain Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="494"/>
                    <count group_id="O2" value="490"/>
                    <count group_id="O3" value="244"/>
                    <count group_id="O4" value="240"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.68" spread="25.587"/>
                    <measurement group_id="O2" value="70.42" spread="24.688"/>
                    <measurement group_id="O3" value="68.51" spread="26.163"/>
                    <measurement group_id="O4" value="69.44" spread="26.016"/>
                    <measurement group_id="O5" value="69.30" spread="25.766"/>
                    <measurement group_id="O6" value="68.59" spread="26.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: Bodily-Pain Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="28.525"/>
                    <measurement group_id="O2" value="-1.47" spread="25.779"/>
                    <measurement group_id="O3" value="-2.92" spread="23.486"/>
                    <measurement group_id="O4" value="-4.36" spread="25.935"/>
                    <measurement group_id="O5" value="-3.60" spread="22.138"/>
                    <measurement group_id="O6" value="-4.46" spread="33.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: General Health Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="493"/>
                    <count group_id="O2" value="489"/>
                    <count group_id="O3" value="240"/>
                    <count group_id="O4" value="238"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.99" spread="21.563"/>
                    <measurement group_id="O2" value="55.44" spread="20.768"/>
                    <measurement group_id="O3" value="54.45" spread="18.690"/>
                    <measurement group_id="O4" value="52.42" spread="20.028"/>
                    <measurement group_id="O5" value="51.21" spread="18.707"/>
                    <measurement group_id="O6" value="52.58" spread="19.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: General Health Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="213"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="18.744"/>
                    <measurement group_id="O2" value="-2.12" spread="20.595"/>
                    <measurement group_id="O3" value="-2.28" spread="16.752"/>
                    <measurement group_id="O4" value="-0.52" spread="22.035"/>
                    <measurement group_id="O5" value="-5.64" spread="18.270"/>
                    <measurement group_id="O6" value="1.21" spread="21.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Vitality Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="486"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="239"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.48" spread="20.966"/>
                    <measurement group_id="O2" value="52.21" spread="19.842"/>
                    <measurement group_id="O3" value="50.63" spread="19.130"/>
                    <measurement group_id="O4" value="50.64" spread="21.069"/>
                    <measurement group_id="O5" value="51.30" spread="19.703"/>
                    <measurement group_id="O6" value="50.33" spread="20.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: Vitality Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="214"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="19.857"/>
                    <measurement group_id="O2" value="-0.73" spread="19.033"/>
                    <measurement group_id="O3" value="-4.67" spread="17.934"/>
                    <measurement group_id="O4" value="0.40" spread="20.822"/>
                    <measurement group_id="O5" value="-6.71" spread="20.236"/>
                    <measurement group_id="O6" value="1.03" spread="19.829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Social Functioning Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="494"/>
                    <count group_id="O2" value="490"/>
                    <count group_id="O3" value="244"/>
                    <count group_id="O4" value="239"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.46" spread="24.451"/>
                    <measurement group_id="O2" value="71.53" spread="24.394"/>
                    <measurement group_id="O3" value="69.67" spread="24.581"/>
                    <measurement group_id="O4" value="72.23" spread="24.699"/>
                    <measurement group_id="O5" value="69.02" spread="24.688"/>
                    <measurement group_id="O6" value="69.53" spread="25.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: Social Functioning Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="25.575"/>
                    <measurement group_id="O2" value="-3.30" spread="24.912"/>
                    <measurement group_id="O3" value="-5.69" spread="22.184"/>
                    <measurement group_id="O4" value="-2.08" spread="27.724"/>
                    <measurement group_id="O5" value="-10.76" spread="34.350"/>
                    <measurement group_id="O6" value="-0.52" spread="25.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Role-Emotional Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="491"/>
                    <count group_id="O2" value="485"/>
                    <count group_id="O3" value="241"/>
                    <count group_id="O4" value="238"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.87" spread="40.653"/>
                    <measurement group_id="O2" value="65.57" spread="40.015"/>
                    <measurement group_id="O3" value="62.86" spread="42.715"/>
                    <measurement group_id="O4" value="62.61" spread="41.280"/>
                    <measurement group_id="O5" value="60.29" spread="41.393"/>
                    <measurement group_id="O6" value="64.26" spread="41.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: Role-Emotional Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                    <count group_id="O2" value="214"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="49.950"/>
                    <measurement group_id="O2" value="0.47" spread="43.513"/>
                    <measurement group_id="O3" value="-12.22" spread="42.532"/>
                    <measurement group_id="O4" value="4.17" spread="44.656"/>
                    <measurement group_id="O5" value="-13.18" spread="42.501"/>
                    <measurement group_id="O6" value="-3.55" spread="48.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mental Health Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="486"/>
                    <count group_id="O3" value="242"/>
                    <count group_id="O4" value="239"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.01" spread="19.818"/>
                    <measurement group_id="O2" value="66.24" spread="19.060"/>
                    <measurement group_id="O3" value="65.42" spread="17.658"/>
                    <measurement group_id="O4" value="65.15" spread="19.233"/>
                    <measurement group_id="O5" value="62.30" spread="17.347"/>
                    <measurement group_id="O6" value="63.61" spread="18.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: Mental Health Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="214"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="19.715"/>
                    <measurement group_id="O2" value="2.31" spread="18.095"/>
                    <measurement group_id="O3" value="-3.91" spread="19.897"/>
                    <measurement group_id="O4" value="2.33" spread="17.524"/>
                    <measurement group_id="O5" value="-0.29" spread="21.989"/>
                    <measurement group_id="O6" value="-2.06" spread="20.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mental Component Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="488"/>
                    <count group_id="O2" value="480"/>
                    <count group_id="O3" value="237"/>
                    <count group_id="O4" value="235"/>
                    <count group_id="O5" value="114"/>
                    <count group_id="O6" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.40" spread="11.130"/>
                    <measurement group_id="O2" value="45.63" spread="10.272"/>
                    <measurement group_id="O3" value="45.13" spread="10.932"/>
                    <measurement group_id="O4" value="45.31" spread="10.907"/>
                    <measurement group_id="O5" value="44.00" spread="10.702"/>
                    <measurement group_id="O6" value="45.03" spread="10.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: Mental Component Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="211"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="12.415"/>
                    <measurement group_id="O2" value="0.87" spread="10.028"/>
                    <measurement group_id="O3" value="-2.55" spread="10.328"/>
                    <measurement group_id="O4" value="1.97" spread="10.657"/>
                    <measurement group_id="O5" value="-2.59" spread="12.895"/>
                    <measurement group_id="O6" value="0.08" spread="10.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Physical Component Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="488"/>
                    <count group_id="O2" value="480"/>
                    <count group_id="O3" value="237"/>
                    <count group_id="O4" value="235"/>
                    <count group_id="O5" value="114"/>
                    <count group_id="O6" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.53" spread="9.884"/>
                    <measurement group_id="O2" value="44.44" spread="10.048"/>
                    <measurement group_id="O3" value="43.74" spread="9.739"/>
                    <measurement group_id="O4" value="43.56" spread="10.267"/>
                    <measurement group_id="O5" value="43.68" spread="10.359"/>
                    <measurement group_id="O6" value="43.15" spread="10.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: Physical Component Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                    <count group_id="O2" value="211"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="9.373"/>
                    <measurement group_id="O2" value="-1.94" spread="10.532"/>
                    <measurement group_id="O3" value="-2.29" spread="8.929"/>
                    <measurement group_id="O4" value="-3.25" spread="9.998"/>
                    <measurement group_id="O5" value="-2.70" spread="8.860"/>
                    <measurement group_id="O6" value="-1.59" spread="10.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384</title>
        <description>The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. The EQ-5D provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to indicate whether he or she has (1) &quot;no problems&quot;, (2) &quot;some problems&quot;, or (3) &quot;severe problems&quot;. A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 384</time_frame>
        <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384</title>
          <description>The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. The EQ-5D provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to indicate whether he or she has (1) &quot;no problems&quot;, (2) &quot;some problems&quot;, or (3) &quot;severe problems&quot;. A positive change from baseline indicates improvement.</description>
          <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="502"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="248"/>
                <count group_id="O5" value="118"/>
                <count group_id="O6" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="488"/>
                    <count group_id="O2" value="484"/>
                    <count group_id="O3" value="239"/>
                    <count group_id="O4" value="239"/>
                    <count group_id="O5" value="115"/>
                    <count group_id="O6" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.210"/>
                    <measurement group_id="O2" value="0.73" spread="0.222"/>
                    <measurement group_id="O3" value="0.72" spread="0.223"/>
                    <measurement group_id="O4" value="0.71" spread="0.244"/>
                    <measurement group_id="O5" value="0.71" spread="0.246"/>
                    <measurement group_id="O6" value="0.72" spread="0.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="212"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.251"/>
                    <measurement group_id="O2" value="0.00" spread="0.233"/>
                    <measurement group_id="O3" value="-0.07" spread="0.269"/>
                    <measurement group_id="O4" value="0.00" spread="0.249"/>
                    <measurement group_id="O5" value="-0.04" spread="0.253"/>
                    <measurement group_id="O6" value="-0.03" spread="0.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384</title>
        <description>The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. In EQ-VAS participants are asked to rate their current health on a 20 centimeter (cm) scale from 0 to 100 where 0 represents &quot;worst imaginable health state&quot; and 100 represents &quot;best imaginable health state&quot;. A positive change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 384</time_frame>
        <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384</title>
          <description>The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. In EQ-VAS participants are asked to rate their current health on a 20 centimeter (cm) scale from 0 to 100 where 0 represents &quot;worst imaginable health state&quot; and 100 represents &quot;best imaginable health state&quot;. A positive change from baseline indicates improvement.</description>
          <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="502"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="248"/>
                <count group_id="O5" value="118"/>
                <count group_id="O6" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="488"/>
                    <count group_id="O3" value="243"/>
                    <count group_id="O4" value="238"/>
                    <count group_id="O5" value="113"/>
                    <count group_id="O6" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.97" spread="18.460"/>
                    <measurement group_id="O2" value="70.48" spread="19.993"/>
                    <measurement group_id="O3" value="70.40" spread="17.630"/>
                    <measurement group_id="O4" value="69.44" spread="19.907"/>
                    <measurement group_id="O5" value="66.80" spread="18.846"/>
                    <measurement group_id="O6" value="69.07" spread="20.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                    <count group_id="O2" value="215"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="19.631"/>
                    <measurement group_id="O2" value="-1.67" spread="18.855"/>
                    <measurement group_id="O3" value="-7.24" spread="18.419"/>
                    <measurement group_id="O4" value="-3.17" spread="22.003"/>
                    <measurement group_id="O5" value="-1.71" spread="25.330"/>
                    <measurement group_id="O6" value="-4.11" spread="16.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Function Test Scores at Week 384</title>
        <description>Participants were tested using the contrast level of 100%, 2.5%, and 1.25% charts, and the scores were defined as the number of letters identified correctly for each chart (the maximum score was 60). Higher scores indicate better functioning. A positive change from baseline indicates better functioning.</description>
        <time_frame>Baseline, Week 384</time_frame>
        <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
        <group_list>
          <group group_id="O1">
            <title>BG00012 240 mg BID (Prior BG00012 240 mg BID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received BG00012 240 mg BID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg TID (Prior BG00012 240 mg TID)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received BG00012 240 mg TID in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg BID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O4">
            <title>BG00012 240 mg TID (Prior BG00012 Matched Placebo)</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received placebo matched to BG00012 in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O5">
            <title>BG00012 240 mg BID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years. Participants who had received Glatiramer Acetate (GA) in the previous studies were included in this arm group.</description>
          </group>
          <group group_id="O6">
            <title>BG00012 240 mg TID (Prior Glatiramer Acetate [GA])</title>
            <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years. Participants who had received GA in the previous studies were included in this arm group.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Function Test Scores at Week 384</title>
          <description>Participants were tested using the contrast level of 100%, 2.5%, and 1.25% charts, and the scores were defined as the number of letters identified correctly for each chart (the maximum score was 60). Higher scores indicate better functioning. A positive change from baseline indicates better functioning.</description>
          <population>ITT population included participants who had entered study NCT00835770 and received at least one dose of study treatment. 'Number Analyzed' =Number of participants analyzed at specific timepoint. Data for this OM was summarized as per treatment received in previous studies (NCT00420212 and NCT00451451).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="502"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="248"/>
                <count group_id="O5" value="118"/>
                <count group_id="O6" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: 100% Chart</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="502"/>
                    <count group_id="O3" value="249"/>
                    <count group_id="O4" value="248"/>
                    <count group_id="O5" value="118"/>
                    <count group_id="O6" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" spread="7.95"/>
                    <measurement group_id="O2" value="55.0" spread="7.84"/>
                    <measurement group_id="O3" value="55.1" spread="7.26"/>
                    <measurement group_id="O4" value="54.8" spread="7.12"/>
                    <measurement group_id="O5" value="54.3" spread="8.26"/>
                    <measurement group_id="O6" value="55.0" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: 100% Chart</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="6.76"/>
                    <measurement group_id="O2" value="-1.9" spread="6.81"/>
                    <measurement group_id="O3" value="-1.4" spread="8.48"/>
                    <measurement group_id="O4" value="-1.2" spread="7.53"/>
                    <measurement group_id="O5" value="-1.6" spread="8.05"/>
                    <measurement group_id="O6" value="-0.7" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 2.5% Chart</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="502"/>
                    <count group_id="O3" value="249"/>
                    <count group_id="O4" value="248"/>
                    <count group_id="O5" value="118"/>
                    <count group_id="O6" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="12.17"/>
                    <measurement group_id="O2" value="32.6" spread="11.76"/>
                    <measurement group_id="O3" value="32.4" spread="11.42"/>
                    <measurement group_id="O4" value="32.3" spread="11.99"/>
                    <measurement group_id="O5" value="31.8" spread="12.36"/>
                    <measurement group_id="O6" value="31.7" spread="12.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: 2.5% Chart</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="10.77"/>
                    <measurement group_id="O2" value="-3.3" spread="10.43"/>
                    <measurement group_id="O3" value="-1.5" spread="11.77"/>
                    <measurement group_id="O4" value="-4.9" spread="11.14"/>
                    <measurement group_id="O5" value="-4.0" spread="11.90"/>
                    <measurement group_id="O6" value="-2.1" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 1.25% Chart</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="499"/>
                    <count group_id="O2" value="502"/>
                    <count group_id="O3" value="249"/>
                    <count group_id="O4" value="247"/>
                    <count group_id="O5" value="118"/>
                    <count group_id="O6" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="12.45"/>
                    <measurement group_id="O2" value="24.2" spread="12.28"/>
                    <measurement group_id="O3" value="23.8" spread="12.11"/>
                    <measurement group_id="O4" value="23.7" spread="12.96"/>
                    <measurement group_id="O5" value="23.4" spread="11.76"/>
                    <measurement group_id="O6" value="22.2" spread="13.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 384: 1.25% Chart</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="13.39"/>
                    <measurement group_id="O2" value="-6.0" spread="11.77"/>
                    <measurement group_id="O3" value="-4.1" spread="13.04"/>
                    <measurement group_id="O4" value="-7.4" spread="12.42"/>
                    <measurement group_id="O5" value="-6.7" spread="13.78"/>
                    <measurement group_id="O6" value="-5.0" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of the study up to follow-up (up to Week 561)</time_frame>
      <desc>Safety population included all participants who had any post-baseline safety follow-up in study NCT00835770, defined as any treatment emergent AE in Study NCT00835770 or any post-baseline laboratory, vital signs, or physical exam assessment in study NCT00835770, and received at least one dose of study treatment in study NCT00835770.</desc>
      <group_list>
        <group group_id="E1">
          <title>BG00012 240 mg BID</title>
          <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, BID and 2 matching placebo capsules QD for up to 8 years.</description>
        </group>
        <group group_id="E2">
          <title>BG00012 240 mg TID</title>
          <description>Participants received BG00012 240 mg, 2 capsules (120 mg each) orally, TID for up to 8 years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="279" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="272" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Wolff-parkinson-white syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cytogenetic abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Limb malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Retinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastrointestinal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Capsular contracture associated with breast implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Serositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Treatment failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Peritonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy (PML)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Spinal deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenolymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bowenoid papulosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cervix neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Glioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Mesothelioma malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pharyngeal neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Squamous endometrial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Radiculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Relapsing-remitting multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Uhthoff's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Complication of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Anorexia nervosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Burnout syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Morbid thoughts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Psychotic behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pulmonary sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominoplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Aortic valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bladder neck suspension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bunion operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cochlea implant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cystocele repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Female sterilisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Mammoplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Medical device change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ovarian cystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Postoperative care</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="779" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="767" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Albumin urine present</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="324" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="335" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="868"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>US Biogen Clinical Trial Center</name_or_title>
      <organization>Biogen</organization>
      <phone>866-633-4636</phone>
      <email>clinicaltrials@biogen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

